VanEck Associates’s Insys Therapeutics, Inc. INSY Stock Holding History

VanEck Associates’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-866	Closed	-$8K	–	914
2016 Q4	$8K	Buy	866 +428	+98%	+$4.83K	﹤0.01%	880
2016 Q3	$5K	Buy	438 +204	+87%	+$3.1K	﹤0.01%	866
2016 Q2	$3K	Buy	234 +23	+11%	+$335	﹤0.01%	861
2016 Q1	$3K	Buy	+211	New	+$4.01K	﹤0.01%	815

Other funds holding INSY

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FHAM

Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCP

Fine Capital Partners New York $563M AUM 7.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

VanEck Associates's INSY Position: Q1 2017 in Review

VanEck Associates sold out of Insys Therapeutics, Inc. (INSY) in Q1 2017, closing a stake of 866 shares — an estimated $8K sold.

VanEck Associates first reported a position in INSY in Q1 2016 and held it in 4 quarters. The position peaked at $8K in Q4 2016. 116 funds tracked by Wall St. Rank hold INSY as of Q1 2017.

VanEck Associates reported no remaining Insys Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
VanEck Associates sold 866 Insys Therapeutics, Inc. shares in Q1 2017, an estimated $8K.
VanEck Associates first reported a position in Insys Therapeutics, Inc. in Q1 2016 and held it in 4 quarters.
VanEck Associates's Insys Therapeutics, Inc. position peaked at $8K in Q4 2016.
116 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q1 2017.

Based on VanEck Associates's 13F filing for Q1 2017, filed 11 May 2017.